Search Results - "YAVZORI, M."

Early drug and anti‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy by Bar‐Yoseph, H., Levhar, N., Selinger, L., Manor, U., Yavzori, M., Picard, O., Fudim, E., Kopylov, U., Eliakim, R., Ben‐Horin, S., Chowers, Y., Ungar, B.

“…Summary Background Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with…”
Get full text

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab by Ungar, B., Kopylov, U., Engel, T., Yavzori, M., Fudim, E., Picard, O., Lang, A., Williet, N., Paul, S., Chowers, Y., Bar‐Gil Shitrit, A., Eliakim, R., Ben‐Horin, S., Roblin, X.

“…Summary Background Anti‐adalimumab antibodies (AAA) are associated with loss of clinical response (LOR). Addition of an immunomodulator has been shown to…”
Get full text

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis by Ungar, B., Mazor, Y., Weisshof, R., Yanai, H., Ron, Y., Goren, I., Waizbard, A., Yavzori, M., Fudim, E., Picard, O., Loebstein, R., Kopylov, U., Dotan, I., Chowers, Y., Eliakim, R., Ben‐Horin, S.

“…Summary Background Infliximab is effective as salvage therapy for patients with steroid refractory acute severe ulcerative colitis (UC). Although current data…”
Get full text

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful by Ben-Horin, Shomron, Yavzori, Miri, Katz, Lior, Kopylov, Uri, Picard, Orit, Fudim, Ella, Coscas, Daniel, Bar-Meir, Simon, Goldstein, Itamar, Chowers, Yehuda

“…To localise the immunogenic part of infliximab and evaluate the clinical usefulness of measuring antibodies against infliximab fragments. Observational study…”
Get more information

Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor by Ben‐Horin, S., Ungar, B., Kopylov, U., Lahat, A., Yavzori, M., Fudim, E., Picard, O., Peled, Y., Eliakim, R., Del Tedesco, E., Paul, S., Roblin, X.

“…Summary Background Data on combination‐biologic treatment in (IBD) are still scant. Aim To explore outcomes of patients co‐exposed to anti‐TNF and vedolizumab…”
Get full text

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD by Ben-Horin, S., Mazor, Y., Yanai, H., Ron, Y., Kopylov, U., Yavzori, M., Picard, O., Fudim, E., Maor, Y., Lahat, A., Coscas, D., Eliakim, R., Dotan, I., Chowers, Y.

“…Summary Background Anti‐drug antibodies can be elicited by infliximab and adalimumab, but the rate of their decay after therapy is stopped is unknown. Aim To…”
Get full text

Antigenic response to CT‐P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition by Goncalves, J., Santos, M., Acurcio, R., Iria, I., Gouveia, L., Matos Brito, P., Catarina Cunha‐Santos, A., Barbas, A., Galvão, J., Barbosa, I., Aires da Silva, F., Alcobia, A., Cavaco, M., Cardoso, M., Delgado Alves, J., Carey, J. J., Dörner, T., Eurico Fonseca, J., Palmela, C., Torres, J., Lima Vieira, C., Trabuco, D., Fiorino, G., Strik, A., Yavzori, M., Rosa, I., Correia, L., Magro, F., D'Haens, G., Ben‐Horin, S., Lakatos, P. L., Danese, S.

“…Summary Aim To test the cross‐immunogenicity of anti‐CT‐P13 IBD patients’ sera to CT‐P13/infliximab originator and the comparative antigenicity evoked by…”
Get full text

Berberine Alone and in Conjunction With Immunomodulators Down-regulates Pro-inflammatory CD4+ T-Cells: Implications for a Combined Treatment of Inflammatory Bowel Diseases by Salomon, N, Fudim, E, Picard, O, Yavzori, M, Gamus, D, Elyakim, R, Ben-Horin, S

Get full text

Prevalence of the genes for shigella enterotoxins 1 and 2 among clinical isolates of shigella in Israel by YAVZORI, M., COHEN, D., ORR, N.

“…Two enterotoxins, shigella enterotoxin 1 (SHET1) and shigella enterotoxin 2 (SHET2) have been recently characterized and are believed to play a role in the…”
Get full text

An outbreak of pertussis among young Israeli soldiers by KLEMENT, E., ULIEL, L., ENGEL, I., HASIN, T., YAVZORI, M., ORR, N., DAVIDOVITZ, N., LAHAT, N., SRUGO, I., ZANGVIL, E., COHEN, D.

“…In winter 2001, an outbreak of pertussis involving an estimated 75 people occurred among soldiers serving in an infantry regiment of the Israeli Defense Forces…”
Get full text

A waterborne outbreak of gastroenteritis in the Golan heights due to enterotoxigenic Escherichia coli by HUERTA, M, GROTTO, I, GDALEVICH, M, MIMOUNI, D, GAVRIELI, B, YAVZORI, M, COHEN, D, SHPILBERG, O

“…Over a period of 4 days between May 18-21, 1998, a multifocal outbreak of diarrhea, involving 175 Israel Defence Force soldiers and at least 54 civilians,…”
Get full text

Molecular analysis of noroviruses involved in acute gastroenteritis outbreaks in military units in Israel, 1999-2004 by HALPERIN, T, YAVZORI, M, ORR, N, AMITAI, A, ELEMENT, E, KAYOUF, R, GROTTO, I, HUERTA, M, HADLEY, L. A, MONROE, S. S, COHEN, D

“…The study presented here was conducted to determine the genetic properties of noroviruses (NoVs) identified between 1999 and 2004 in army recruits with acute…”
Get full text

Retrospective analysis of the first clonal outbreak of nalidixic acid-resistant Shigella sonnei shigellosis in Israel by DAGAN, D, ORR, N, YAVZORI, M, YUHAS, Y, MERON, D, ASHKENAZI, S, COHEN, D

“…Reported here is a retrospective molecular analysis of the isolates recovered from the first outbreak of nalidixic acid (NA)-resistant Shigella sonnei…”
Get full text

P109 Using baseline Peripheral blood mononuclear cell (PBMC) transcriptomics of Crohn Disease patients receiving Ustekinumab treatment as a tool to assess potential response at 1 year by Granot, M, Braun, T, Efroni, G, Fudim, E, Yavzori, M, Haj, O, Ben-Horin, S, Kopylov, U, Haberman Ziv, Y

“…Abstract Background Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, is used to treat Crohn Disease (CD) and…”
Get full text

Prospective cohort studies of shigellosis during military field training by COHEN, D, SELA, T, SLEPON, R, YAVZORI, M, AMBAR, R, ORR, N, ROBIN, G, SHPIELBERG, O, ELDAD, A, GREEN, M

“…Epidemiological and clinical features of shigellosis occurring among cohorts of Israeli recruits followed-up for 3-6 months during the summer field training of…”
Get full text

P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease? by Levartovsky, A, Cohen, I, Abitbol, C M, Yavzori, M, Fudim, E, Picard, O, Kopylov, U, Ben-Horin, S, Ungar, B

“…Abstract Background Vedolizumab trough serum levels have been associated with clinical and endoscopic response in patients with inflammatory bowel disease…”
Get full text

P017 Fecal wash host transcriptomics identifies inflammation throughout the colon and terminal ileum by Dan, S, Ungar, B, Ben-Moshe, S, Bahar Halpern, K, Yavzori, M, Fudim, E, Picard, O, Abitbol, C M, Harnik, S, Kopylov, U, Ben-Horin, S, Itzkovitz, S

“…Abstract Background Non-invasive modalities for assessing active endoscopic and histological inflammation in Crohn’s disease and Ulcerative Colitis patients…”
Get full text

Detection of enterotoxigenic Escherichia coli in stool specimens by polymerase chain reaction by Yavzori, M, Porath, N, Ochana, O, Dagan, R, Orni-Wasserlauf, R, Cohen, D

“…A polymerase chain reaction (PCR) protocol for rapid (7 h) detection of enterotoxigenic Escherichia coli (ETEC) is described. This protocol has been validated…”
Get full text

P046 Crohn Disease (CD) untargeted fecal metabolome shows strong correlation with specific salivary associated microbial taxa, and with disease activity by Levhar, N, Hadar, R, Braun, T, Efroni, G, Abramovich, I, Gottlieb, E, Granot, M, Neuman, S, Selinger, L, Picard, O, Yavzori, M, Lahat, A, Eliakim, R, Weiss, B, Kopylov, U, Ben-Horin, S, Amir, A, Haberman Ziv, Y

“…Abstract Background The fecal metabolome is comprised from derivatives of the gut microbiome, the host, the environment, and the diet. Thus, it is a central…”
Get full text

P056 Exposures linked with urban and rural living indicate that living in rural area but spending above 50% of daily-life in urban environment is linked with reduction in alpha-diversity, reduced rural index, and reduced microbial health index mirroring CD profile by Haberman Ziv, Y, Feng, R, Mao, R, Braun, T, Zhuo, S, Toren, I, Efroni, G, Malik, A, Picard, O, Yavzori, M, Hadar, R, Amir, A, Chen, M, Ben-Horin, S

“…Abstract Background Efforts to delineate factors linked with rural to urban transition, paralleling the staggering rise in CD incidence, have been hampered by…”
Get full text